newsfilter
← Latest News
Business Wire·

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

- Company expects to receive a negative opinion following oral explanation feedback and intends to request re‑examination upon review of formal adoption. Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that